CL2019000268A1 - Composición de cannabis. - Google Patents

Composición de cannabis.

Info

Publication number
CL2019000268A1
CL2019000268A1 CL2019000268A CL2019000268A CL2019000268A1 CL 2019000268 A1 CL2019000268 A1 CL 2019000268A1 CL 2019000268 A CL2019000268 A CL 2019000268A CL 2019000268 A CL2019000268 A CL 2019000268A CL 2019000268 A1 CL2019000268 A1 CL 2019000268A1
Authority
CL
Chile
Prior art keywords
cannabis
extract
skin disorder
cannabis composition
treat
Prior art date
Application number
CL2019000268A
Other languages
English (en)
Inventor
Harry Karelis
Mara Gordon
Stewart Smith
Stewart Washer
Original Assignee
Zelda Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61072439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019000268(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zelda Therapeutics Operations Pty Ltd filed Critical Zelda Therapeutics Operations Pty Ltd
Publication of CL2019000268A1 publication Critical patent/CL2019000268A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCIÓN SE REFIERE A UN MÉTODO PARA TRATAR UN TRASTORNO DE LA PIEL. EN PARTICULAR, LA INVENCIÓN PROPORCIONA UN MÉTODO PARA TRATAR UN TRASTORNO DE LA PIEL, QUE COMPRENDE ADMINISTRAR A UN PACIENTE QUE LO NECESITE UNA CANTIDAD EFICAZ DE LA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UN EXTRACTO DE CANNABIS Y OPCIONALMENTE UNO O MÁS PORTADORES, DILUYENTES, ADYUVANTES, EXCIPIENTES FARMACÉUTICAMENTE ACEPTABLES O CUALQUIER COMBINACIÓN DE ESTOS, EL EXTRACTO DE CANNABIS QUE COMPRENDE AL MENOS 75 % EN PESO DE UN CANNABINOIDE PRINCIPAL.
CL2019000268A 2016-08-03 2019-01-31 Composición de cannabis. CL2019000268A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662370303P 2016-08-03 2016-08-03

Publications (1)

Publication Number Publication Date
CL2019000268A1 true CL2019000268A1 (es) 2019-10-04

Family

ID=61072439

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000268A CL2019000268A1 (es) 2016-08-03 2019-01-31 Composición de cannabis.

Country Status (11)

Country Link
US (2) US20190307719A1 (es)
EP (1) EP3493799A4 (es)
JP (1) JP2019523282A (es)
KR (1) KR20190033590A (es)
CN (1) CN109789124A (es)
AU (5) AU2017307644B2 (es)
CA (1) CA3031811A1 (es)
CL (1) CL2019000268A1 (es)
PE (1) PE20200676A1 (es)
SG (1) SG11201900596XA (es)
WO (1) WO2018023164A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019001285A (es) 2016-08-03 2019-06-13 Zelda Therapeutics Operations Pty Ltd Composicion de cannabis.
AU2017307644B2 (en) 2016-08-03 2019-06-20 Zelira Therapeutics Operations Pty Ltd Cannabis composition
JP2019526541A (ja) 2016-08-03 2019-09-19 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 大麻組成物
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
US11484510B2 (en) * 2017-08-28 2022-11-01 Apirx Pharmaceutical Usa, Llc Method to treat vitiligo
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
EP3793542A4 (en) * 2018-05-14 2022-03-30 Buzzelet Development And Technologies Ltd TERPENE-ENRICHED CANNABINOID COMPOSITIONS AND THEIR USES IN THE TREATMENT OF INFECTIOUS DISEASES
US10736869B2 (en) * 2018-07-16 2020-08-11 ECS Health Sciences, Inc. Compositions and methods related to cannabinoids, terpenoids and essential oils
US11013715B2 (en) * 2018-07-19 2021-05-25 Vertosa, Inc. Nanoemulsion hydrophobic substances
IL261774B (en) * 2018-09-13 2020-04-30 Unv Medicine Ltd Compositions for treating dermatological conditions
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
WO2020086291A1 (en) * 2018-10-22 2020-04-30 Jones Lisa Marie Topical compositions incorporating cannabis
WO2020123383A1 (en) * 2018-12-10 2020-06-18 Natural Extraction Systems, LLC Compositions with novel cannabinoid and terpene profiles
WO2020129044A1 (en) * 2018-12-19 2020-06-25 Pathway RX Inc. Novel cannabis lines and extracts for skin rejuvenation and skin protection
WO2020129043A1 (en) * 2018-12-19 2020-06-25 Pathway RX Inc. Novel cannabis sativa lines and extracts with anti-cancer properties
WO2020129045A1 (en) * 2018-12-19 2020-06-25 Pathway RX Inc. Novel cannabis lines and extracts for treating skin disorders
CN114269333A (zh) * 2018-12-25 2022-04-01 Epm (Ip)公司 用于美容或可食用组合物的大麻二酚酸酯
EP3906025A4 (en) * 2019-01-04 2022-09-21 Columbia Care LLC CANNABINOID TOPICAL FORMULATIONS
US11246310B2 (en) * 2019-02-08 2022-02-15 Global Biolife Inc. Insect repelling composition
US20200345686A1 (en) * 2019-04-30 2020-11-05 Vcp Ip Holdings, Llc, Limited Liability Company Delaware Compositions and methods for treating skin and neuropathic conditions and disorders
US10717056B1 (en) 2019-09-09 2020-07-21 Michael Cem Gokay Method and apparatus for purification of cannabinoid extracts
US20210093539A1 (en) * 2019-09-30 2021-04-01 Concept Matrix Solutions Topical cosmetic
US20210113490A1 (en) * 2019-10-21 2021-04-22 Avicanna Inc. Topical cannabinoid compositions for clear skin
US10941131B1 (en) * 2019-10-28 2021-03-09 Pure Tonic Concentrates, LLC Conversion of cannabidiol or delta-9 tetrahydrocannabinolic acid to delta-9 tetrahydrocannabinol and delta-8 tetrahydrocannabinol in nontoxic heterogeneous mixtures
WO2021127559A1 (en) * 2019-12-19 2021-06-24 Natural Extraction Systems, LLC Compositions comprising cannabinoid anions and anti-nucleating agents
US11590187B2 (en) * 2020-01-14 2023-02-28 Shaman Naturals, Llc Antimicrobial compositions
US20210346276A1 (en) * 2020-05-05 2021-11-11 Gm Pharmaceuticals, Inc. Skincare compositions containing cannabidiol
US20210369802A1 (en) * 2020-06-01 2021-12-02 James Chuang Cannabis plant formulations and methods of delivery
US20220054446A1 (en) * 2020-08-18 2022-02-24 Yvette Rose Webb Targeted treatment with a topical cream of cannabinoids, terpenes, and essential oils
WO2023152748A1 (en) * 2022-02-13 2023-08-17 Reagenics Research Ltd. Plant-based skin preparations and use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
JP2004002237A (ja) * 2002-05-31 2004-01-08 Noriko Yagi 老化防止ハーブ
EP1559423A1 (en) * 2004-02-02 2005-08-03 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Medicinal acidic cannabinoids
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
EP2444081B1 (en) * 2010-10-19 2015-04-08 Parenteral, A.S. A composition for the treatment of inflammatory diseases comprising boswellic acids and cannabidiol
US20120264818A1 (en) * 2011-04-15 2012-10-18 Jon Newland Topical Compositions with Cannabis Extracts
US20130184354A1 (en) * 2012-01-13 2013-07-18 Donna K. Jackson Silicone and Hylauronic Acid (HLA) Delivery Systems for Products by Sustainable Processes for Medical Uses Including Wound Management
US20130274321A1 (en) * 2012-03-30 2013-10-17 Jon Newland Topical Compositions with Cannabis Extracts
SI2844243T1 (sl) * 2012-05-03 2020-02-28 Echo Pharmaceuticals B.V. Metoda za pripravo izolata iz rastline konoplje, ki obsega delta-9-tetrahidrokanabinol
WO2014100231A1 (en) * 2012-12-18 2014-06-26 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
EP2968259B1 (en) * 2013-03-14 2022-09-14 SC Laboratories Inc. Bioactive concentrates and uses thereof
MX2015013202A (es) * 2013-03-15 2016-04-07 Biotech Inst Llc Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
CN105764504A (zh) * 2013-09-26 2016-07-13 罗纳德·D·塞库拉 引入大麻种衍生的植物药品的局部治疗
SI3062606T1 (sl) * 2013-10-29 2019-09-30 Biotech Institute, Llc Gojenje, priprava, predelava in uporaba posebnega kanabisa
JP6377423B2 (ja) * 2014-06-17 2018-08-22 ロート製薬株式会社 外用組成物
WO2015200049A1 (en) * 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
EP3217995A1 (en) * 2014-08-25 2017-09-20 Janing Holding ApS Device with compositions for delivery to the lungs, the oral mucosa and the brain
CA2859930A1 (en) * 2014-09-22 2016-03-22 Antony Paul Hornby A cannabis topical from heat treated cocount oil
EP3209312A1 (en) * 2014-10-21 2017-08-30 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
US20160309774A1 (en) * 2015-04-27 2016-10-27 Michael D. Wand Terpene carrier
EP3380096A4 (en) * 2015-11-24 2019-10-23 Constance Therapeutics, Inc. CANNABIS OIL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
AU2016367036B2 (en) * 2015-12-09 2019-04-18 Poviva Corp. Methods for formulating orally ingestible compositions comprising lipophilic active agents
CA3011185A1 (en) * 2016-01-20 2017-07-27 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
IL307857A (en) * 2016-03-16 2023-12-01 Buzzelet Development And Technologies Ltd Cannobinoid compounds are rich in terpenes
IL246790A0 (en) * 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
AU2017307644B2 (en) 2016-08-03 2019-06-20 Zelira Therapeutics Operations Pty Ltd Cannabis composition

Also Published As

Publication number Publication date
KR20190033590A (ko) 2019-03-29
US20220362208A1 (en) 2022-11-17
AU2018100921A4 (en) 2018-08-02
AU2019208177B2 (en) 2021-07-01
CN109789124A (zh) 2019-05-21
JP2019523282A (ja) 2019-08-22
AU2017307644B2 (en) 2019-06-20
EP3493799A1 (en) 2019-06-12
EP3493799A4 (en) 2020-04-01
WO2018023164A1 (en) 2018-02-08
AU2019208177A1 (en) 2019-08-08
PE20200676A1 (es) 2020-06-11
AU2017307644A1 (en) 2018-07-05
AU2018100921B4 (en) 2019-02-14
AU2021240296B2 (en) 2024-03-07
AU2021240296A1 (en) 2021-10-28
AU2024203468A1 (en) 2024-06-13
US20190307719A1 (en) 2019-10-10
CA3031811A1 (en) 2018-02-08
SG11201900596XA (en) 2019-02-27

Similar Documents

Publication Publication Date Title
CL2019000268A1 (es) Composición de cannabis.
CO2019001043A2 (es) Composición de cannabis
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CO2019001044A2 (es) Composición de cannabis
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
AR101740A1 (es) Terapia de combinación y composiciones
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
ECSP19057403A (es) Usos terapéuticos de un polvo de insectos
MX2016011667A (es) Composiciones topicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad.
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
CO2019002245A2 (es) Combinación de agonistas de fxr
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
NI202000052A (es) Terapia de combinación para tratar o prevenir el cáncer
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
MX2020001164A (es) Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico.
BR112019006174A2 (pt) proteina terapêutica
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
BR112019001130A2 (pt) uso de lactama e composição farmacêutica
BR112018012126A2 (pt) ?adjuvante, método para prevenir e/ou tratar uma doença autoimune, e, uso de um adjuvante?
BR112019008516A2 (pt) derivado de 3,4-bipiridil pirazol, e método de preparação para o mesmo e aplicação médica do mesmo
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
GB2550750A (en) Anthelmintic compounds